Physician profile
Beata Fiuk
NPI 1336574524
$9,059.50
in general payments reported to CMS, 2019-2025
30 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,190 · 2022: $1,474 · 2023: $1,945 · 2024: $2,181 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,395.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,422.86 | 2021-2025 | Fasenra, Breztri, Farxiga |
| Abbvie INC. | $1,254.62 | 2021-2025 | |
| Novo Nordisk INC | $852.30 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $817.93 | 2021-2025 | Descovy, Yeztugo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $551.49 | 2023-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.67 | 2021-2025 | Jardiance |
| Amgen INC. | $501.00 | 2023-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $415.43 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $400.21 | 2024-2025 | Nucala |
| Genzyme Corporation | $198.93 | 2022-2025 | |
| Lilly USA, LLC | $162.44 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $143.12 | 2022 | |
| Lundbeck LLC | $139.49 | 2025 | Rexulti |
| Exact Sciences Corporation | $101.07 | 2024-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $71.46 | 2024-2025 | Loreev Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $69.04 | 2021-2024 | Livalo |
| Ardelyx, INC. | $54.20 | 2025 | Ibsrela |
| Astellas Pharma US INC | $52.77 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $47.53 | 2022 | |
| Sanofi-Aventis U.S. LLC | $42.47 | 2024-2025 | |
| Phadia US INC. | $41.77 | 2024-2025 | Immunocap |
| Horizon Therapeutics Plc | $32.44 | 2022 | |
| Merck Sharp & Dohme LLC | $30.99 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $27.45 | 2025 | Rexulti |
| Amarin Pharma, INC. | $24.19 | 2021 | |
| Pfizer INC. | $23.58 | 2025 | |
| Idorsia Pharmaceuticals US INC | $21.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.74 | 2022 | |
| Hologic Sales and Service, LLC | $19.70 | 2024 | Aptima |
| Aimmune Therapeutics, INC. | $17.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beata Fiuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.